PR Newswire | Jan 15, 2021 03:45AM EST

01/15 02:44 CST

Agenda for Calliditas virtual R&D Day on January 20, 2021 STOCKHOLM, Jan. 15, 2021

STOCKHOLM, Jan. 15, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas")(Nasdaq OMX - CALTX) (NASDAQ - CALT) today announced the program for the upcoming virtual R&D Day for investors, analysts and journalists on January 20, 2021, which will take place between 1pm and 5pm CET. The R&D Day will feature presentations from executive management and Key Opinion Leaders and will be webcast live and accessible at: https://tv.streamfabriken.com/calliditas-therapeutics-cmd-january-2021.

The agenda will be as follows:

Introduction &1:00pm Corporate CEO Ren?e Aguiar-Lucander overview

Pathophysiology of IgA1:20pm nephropathy & Professor Jonathan Barratt Nefecon Clinical Biomarker Data

A Review of the1:40pm Phase 3 NefIgArd CMO Dr Richard Phillipson Trial Data

Commentary on the2:00pm NefIgArd Phase 3 Professor Jonathan Barratt Data

2:10pm Regulatory Review Vice President of Regulatory Affairs Frank Bringstrup of Nefecon

2:20pm Live Q&A Session Professor Jonathan Barratt, Dr Richard Phillipson & Frank Bringstrup

Market Access &2:40pm Preparations for Head of North America Commercial, Andrew Udell, & Vice Commercialization President Market Access, Christopher Ngai in the USA

3:10pm Live Q&A Session Andrew Udell and Christopher Ngai

3:20pm Overview of NOX Calliditas' Medical Advisor, Dr Philippe Wiesel Inhibitors

Setanaxib - Professor Gareth3:40pm Applications in Thomas Oncology

Clinical4:00pm Development - Dr Richard Phillipson Pipeline Review

4:15pm Positioning Ren?e Aguiar-Lucander overview

Dr Philippe Wiesel, Professor Gareth Thomas, Dr Richard4:25pm Live Q&A Session Phillipson & Ren?e Aguiar-Lucander

Ren?e Aguiar-Lucander, Fredrik Johansson, CFO4:45pm Closing Summary

5:00pm End

The presentations will be made available on the company's website after the end of the meeting. Please note that the Q&A Sessions will only be available to view live.

KOL Biographies:

Professor Jonathan Barratt leads the Renal Research Group within the College of Life Sciences, University of Leicester. His research interests span a range of areas across renal medicine and include glomerular disease, multi-system renal disease and complications of chronic kidney disease, in particular renal associated anemia. He is the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases (RaDaR) and a member of the steering committee for the International IgA Nephropathy Network. He is also a Chief Investigator for five international randomized controlled clinical trials in IgA nephropathy, and has attended both the FDA and EMA as an expert witness for new therapies in IgA nephropathy. He is a member of the FDA and American Society of Nephrology Kidney Health Initiative: Identifying Surrogate Endpoints for Clinical Trials in IgA Nephropathy Work group.

Professor Gareth J. Thomas is Chair and Professor of Experimental Pathology at University Hospital Southampton NHS Foundation. He leads a group that investigates the effect of the tumor microenvironment on tumor development and progression, particularly the role of cancer-associated fibroblasts in regulating immune escape and tumor invasion. Prior to his current position, Gareth Thomas was Professor of Oral Pathology and Consultant in Oral and Maxillofacial Pathology at Bart's and the London. Gareth Thomas trained in Oral & Maxillofacial Pathology at University College Hospital, London and undertook his PhD as an MRC Clinical Fellow at University College London and the Richard Dimblebey Department of Cancer Research.

For further information, please contact

Marie Galay, IR Manager, Calliditas

Tel.: +44 79 55 98 12 45, email: marie.galay@calliditas.com

The information was sent for publication, through the agency of the contact persons set out above, on January 15, 2021 at 9:00 a.m. CET.

About Calliditas

Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas is running a global Phase 3 study within IgAN and, if approved, aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit www.calliditas.com for further information.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/calliditas-therapeutics/r/agenda-for-calliditas-virtual-r-d-day-on-january-20--2021,c3268373

The following files are available for download:

https://mb.cision.com/Main/16574/3268373/1359483.pdf Release

View original content: http://www.prnewswire.com/news-releases/agenda-for-calliditas-virtual-rd-day-on-january-20-2021-301209164.html

SOURCE Calliditas Therapeutics